Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation

被引:36
作者
Sarosiek, Irene [1 ]
Bashashati, Mohammad [1 ]
Alvarez, Alicia [2 ]
Hall, Mark [1 ]
Shankar, Nagasri [1 ]
Gomez, Yvette [1 ]
McCallum, Richard W. [1 ]
Sarosiek, Jerzy [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Div Gastroenterol, El Paso, TX USA
[2] Cleveland Clin Florida, Dept Gastroenterol, Weston, FL USA
关键词
Chronic constipation; Wireless motility capsule; Gastric emptying time; Small; large; whole bowel transit time; Small intestinal bacterial overgrowth; CHLORIDE CHANNEL ACTIVATOR; FREQUENCY;
D O I
10.1016/j.amjms.2016.05.012
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Lubiprostone is an effective treatment for chronic constipation (CC). The mechanism of action of lubiprostone is through increasing fluid secretion and lubrication of the intestinal lumen. The effects of lubiprostone on gastrointestinal transit and small intestinal bacterial overgrowth (SIBO) have not been adequately explored. The current study was designed to investigate whether lubiprostone (1) alters gastrointestinal transit and (2) affects SIBO in patients with constipation. Methods: A total of 29 female patients (mean age = 39 years; range: 19-64) with CC received 2 weeks of lubiprostone (24 mcg b.i.d., P.O.). Stool consistency based on Bristol stool scale and the frequency of bowel movements (BMs) were recorded. Gastric emptying time, small bowel transit time, colon transit time (CTT), combined small and large bowel transit time (SLBTT) and whole gut transit time were measured using wireless motility capsule. The SIBO status was assessed by the lactulose breath test. Data were analyzed using Wilcoxon rank, Mann-Whitney U, Spearman's rank correlation and Chi-square tests. Results: Lubiprostone significantly softened the stool and increased the frequency of BM from median of 2 to 4 times per week. The CTT and SLBTT were significantly shorter in responders to lubiprostone (i.e., those with >= 2 times increase in the number of their weekly BM) compared with nonresponders. The higher frequency of BM after treatment was significantly correlated with the acceleration of CH, SLBTT and whole gut transit time. In all, 17 out of 25 (68%) patients, who were tested for SIBO at baseline, were positive. In addition, 7 out of 17 (41%) SIBO-positive patients became SIBO-negative after lubiprostone treatment (P < 0.05). Conclusions: In CC, lubiprostone improves the frequency of BMs, softens the stool, accelerates intestinal transit and decreases accompanying SIBO. The improvement of SIBO could be explained by the cleansing effect of increased intestinal fluid and mucus combined with enhanced intestinal motility with lubiprostone.
引用
收藏
页码:231 / 238
页数:8
相关论文
共 22 条
[1]
Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon [J].
Bassil, A. K. ;
Borman, R. A. ;
Jarvie, E. M. ;
McArthur-Wilson, R. J. ;
Thangiah, R. ;
Sung, E. Z. H. ;
Lee, K. ;
Sanger, G. J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (01) :126-135
[2]
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers [J].
Camilleri, M ;
Bharucha, AE ;
Ueno, R ;
Burton, D ;
Thomforde, GM ;
Baxter, K ;
McKinzie, S ;
Zinsmeister, AR .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 290 (05) :G942-G947
[3]
Impaired Viscosity of Gastric Secretion and Its Mucin Content as Potential Contributing Factors to the Development of Chronic Constipation [J].
Castro-Combs, Juan ;
Garcia, Cesar J. ;
Majewski, Marek ;
Wallner, Grzegorz ;
Sarosiek, Jerzy .
DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (11) :2730-2734
[4]
Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation [J].
Fukudo, Shin ;
Hongo, Michio ;
Kaneko, Hiroshi ;
Takano, Masahiro ;
Ueno, Ryuji .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (02) :294-U121
[5]
Epidemiology of constipation in North America: A systematic review [J].
Higgins, PDR ;
Johanson, JE .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (04) :750-759
[6]
Lubiprostone Targets Prostanoid Signaling and Promotes Ion Transporter Trafficking, Mucus Exocytosis, and Contractility [J].
Jakab, Robert L. ;
Collaco, Anne M. ;
Ameen, Nadia A. .
DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (11) :2826-2845
[7]
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety [J].
Johanson, J. F. ;
Ueno, R. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (11) :1351-1361
[8]
Lubiprostone: a novel treatment for chronic constipation [J].
Lacy, Brian E. ;
Levy, L. Campbell .
CLINICAL INTERVENTIONS IN AGING, 2008, 3 (02) :357-364
[9]
Stimulation of Mucin, Mucus, and Viscosity during Lubiprostone in Patients with Chronic Constipation may Potentially Lead to Increase of Lubrication [J].
Majewski, Marek ;
Sarosiek, Irene ;
Wallner, Grzegorz ;
Edlavitch, Stanley A. ;
Sarosiek, Jerzy .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2014, 5
[10]
Martin Bradley C, 2006, Manag Care Interface, V19, P43